Life Sciences
Harnessing clinico-genomics from drug discovery to commercialization
Empowering life sciences bring innovative precision therapies to patients faster through the power of real-world linked clinico-genomic datasets in a range of germline therapeutic areas.
Seamless recruitment workflows resulting in highly differentiated, diverse clinico-genomic datasets
Patient Diversity
Rapidly growing program with 1M+ committed clinico-genomic records from a diverse patient population across the US
Unprecedented Depth
Whole Exome+® sequencing (WES) and longitudinal clinical data including lab results with regular data refreshes
Targeted Enrollment
Direct recruitment and enrollment from EHR system based upon Granular genomic and phenotypic signature
Consent
Full consent for recontact for enrollment in research studies, clinical trials, surveys and testing
Accelerate Your Efforts Across the Drug Development Process
Discovery & Preclinical
Target Discovery and Validation
- Understand genetic drivers of disease progression and clinical outcomes of patients with a wide array of conditions
- Validation of drug candidates of interest in custom cohorts and independent dataset(s)
Clinical Development
Patient Identification and Recruitment
- Rapid identification and recruitment based on genetic and/or phenotypic criteria
- FFS whole exome sequencing to drive further genetic insights
Commercialization
Regulatory and Diagnostics
- Post-market safety and efficacy surveillance studies
- CDx development through external global partnerships
Research-Ready linked clinico-genomic cohort for a range of therapeutic areas
Cardiovascular Diseases Cohort Overview Sheet
Clinico-genomic cohort for Cardiovascular conditions with longitudinal clinical data including diagnosis, lab results, prescription data all linked to Exome sequencing data.
Metabolic Diseases Cohort Overview Sheet
GLP-1 agonist treated clinico-genomic cohort of recontactable individuals for major Metabolic conditions like Diabetes and Obesity.
Autoimmune Diseases Cohort Overview Sheet
Linked clinico-genomic cohort covering a diverse population with major conditions like Lupus, IBD, Rheumatoid Arthritis Hashimoto's and many more.
The analysis of these large datasets in collaboration with Renown could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.
John McHutchison, AO, MD
Chief Scientific Officer and Head of Research and Development, Gilead Sciences
Get in Touch
To learn more about how we can work together, complete this form and we’ll be in touch soon.